- Home
- ENTX vs SQNS Comparison
ENTX vs SQNS Comparison
Compare ENTX & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- SQNS
- Stock Information
- Founded
- ENTX 2010
- SQNS 2003
- Country
- ENTX Israel
- SQNS France
- Employees
- ENTX N/A
- SQNS N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- SQNS Semiconductors
- Sector
- ENTX Health Care
- SQNS Technology
- Exchange
- ENTX Nasdaq
- SQNS Nasdaq
- Market Cap
- ENTX 82.2M
- SQNS 147.0M
- IPO Year
- ENTX 2018
- SQNS 2011
- Fundamental
- Price
- ENTX $1.77
- SQNS $9.52
- Analyst Decision
- ENTX Strong Buy
- SQNS Buy
- Analyst Count
- ENTX 1
- SQNS 1
- Target Price
- ENTX $10.00
- SQNS $3.50
- AVG Volume (30 Days)
- ENTX 77.8K
- SQNS 4.0M
- Earning Date
- ENTX 11-07-2025
- SQNS 11-04-2025
- Dividend Yield
- ENTX N/A
- SQNS N/A
- EPS Growth
- ENTX N/A
- SQNS N/A
- EPS
- ENTX N/A
- SQNS 18.54
- Revenue
- ENTX $166,000.00
- SQNS $37,325,000.00
- Revenue This Year
- ENTX N/A
- SQNS N/A
- Revenue Next Year
- ENTX N/A
- SQNS $89.05
- P/E Ratio
- ENTX N/A
- SQNS $0.52
- Revenue Growth
- ENTX 191.23
- SQNS 32.07
- 52 Week Low
- ENTX $1.50
- SQNS $0.73
- 52 Week High
- ENTX $2.79
- SQNS $9.72
- Technical
- Relative Strength Index (RSI)
- ENTX 38.11
- SQNS 95.31
- Support Level
- ENTX $1.83
- SQNS $0.93
- Resistance Level
- ENTX $1.89
- SQNS $0.89
- Average True Range (ATR)
- ENTX 0.11
- SQNS 0.10
- MACD
- ENTX -0.02
- SQNS 0.60
- Stochastic Oscillator
- ENTX 0.00
- SQNS 97.77
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.